Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Carcinoma 1

Interventions

Capecitabine 13Fluorouracil 12Oxaliplatin 9Nivolumab 9Radiotherapy 8Leucovorin 8Cetuximab 8Magnetic Resonance Spectroscopy 6Irinotecan 5pembrolizumab 4encorafenib 4Surgical Procedures, Operative 4Sigmoidoscopy 4Radiotherapy, Intensity-Modulated 4Surveys and Questionnaires 3Standard of Care 3Specimen Handling 3Biopsy 3Bevacizumab 3dostarlimab 2dehydroftorafur 2atezolizumab 2XELOX 2X-Rays 2Observation 2Magnetic Resonance Imaging 2Immunoglobulin G 2Folfox protocol 2Drug Therapy 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Rectal Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡